News | February 10, 2026
Zydus Lifesciences reports strong Q3 & 9M FY26 growth
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
He has been associated with the Zydus Group since 2009
Zydus will work closely with the USFDA to address and resolve the observations in an expeditious manner
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The closing of the Block Acquisition is now expected to be completed by Q3 2025
ANVIMO will be available in dosages of 240 mg and 480 mg
Subscribe To Our Newsletter & Stay Updated
